Jim Simons
CGTX icon

Jim Simons’s Cognition Therapeutics CGTX Stock Holding History

Jim Simons’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$797K Sell
693,288
-423,848
-38% -$502K ﹤0.01% 2416
2026
Q1 		$848K Buy
1,117,136
+147,623
+15% +$172K ﹤0.01% 2352
2025
Q4 		$1.31M Buy
969,513
+256,013
+36% +$416K ﹤0.01% 2126
2025
Q3 		$963K Buy
713,500
+617,100
+640% +$842K ﹤0.01% 2500
2025
Q2 		$29.9K Buy
96,400
+40,700
+73% +$13.7K ﹤0.01% 3444
2025
Q1 		$23.4K Sell
55,700
-35,400
-39% -$20.8K ﹤0.01% 3350
2024
Q4 		$63.9K Buy
91,100
+2,400
+3% +$1.19K ﹤0.01% 3352
2024
Q3 		$41.6K Sell
88,700
-1,018
-1% -$1.05K ﹤0.01% 3362
2024
Q2 		$149K Sell
89,718
-65,982
-42% -$132K ﹤0.01% 3110
2024
Q1 		$283K Buy
155,700
+143,700
+1,198% +$297K ﹤0.01% 3111
2023
Q4 		$22K Buy
+12,000
New +$15.9K ﹤0.01% 3570
2022
Q1 		– Sell
-11,764
Closed -$74K – 4105
2021
Q4 		$74K Buy
+11,764
New +$115K ﹤0.01% 3733

Other funds holding CGTX

BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Hilton Capital Management
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Jim Simons's CGTX Position: Q2 2026 in Review

Jim Simons reduced its Cognition Therapeutics (CGTX) stake by 38% in Q2 2026, selling an estimated $502K and leaving 693,288 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Jim Simons first reported a position in CGTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.31M in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Jim Simons held 693,288 shares of Cognition Therapeutics worth $797K as of Q2 2026.
  • Jim Simons sold 423,848 Cognition Therapeutics shares in Q2 2026, an estimated $502K.
  • Cognition Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2416 holding.
  • Jim Simons first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Jim Simons's Cognition Therapeutics position peaked at $1.31M in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.